Observational studyMedicine2020
Immature platelet fraction: A useful marker for identifying the cause of thrombocytopenia and predicting platelet recovery.
Observational study in Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 59 citations in OpenAlex.
- Immature Platelet Fraction and Absolute Immature Platelet Count as Diagnostic Markers in Pediatric Immune Thrombocytopenia.International journal of laboratory hematology · 2026Article
- Reticulated Platelets and an Optimal Model for Differentiating Thrombocytopenia Etiologies.EJHaem · 2026Article
- Applications of Extended Platelet Profiles in Clinical Practice.Diseases (Basel, Switzerland) · 2026Review
- Platelet-related parameters at initial diagnosis for predicting the risk of chronicity in children with newly diagnosed immune thrombocytopenia.Frontiers in pediatrics · 2026Article
- Linking preclinical models to clinical realities: VEGF/VEGFR inhibitors and thrombotic microangiopathy in cancer therapy.iMetaOmics · 2025Article
- Article
- Early prediction of platelet recovery with immature platelet fraction in patients receiving hematopoietic stem cell transplantation.Annals of hematology · 2024Article
- Thrombocytopenia in dengue infection: mechanisms and a potential application.Expert reviews in molecular medicine · 2024Review
- Article
- Article
- Reference guide for the diagnosis of adult primary immune thrombocytopenia, 2023 edition.International journal of hematology · 2024Article
- Article
- Novel Biomarkers for Diagnosis and Monitoring of Immune Thrombocytopenia.International journal of molecular sciences · 2023Review
- Thrombocytopenia and insufficient thrombopoietin production in human small-for-gestational-age infants.Pediatric research · 2023Article
- Platelets as a Gauge of Liver Disease Kinetics?International journal of molecular sciences · 2022Review
- Preoperative PDW levels predict pulmonary metastasis in patients with hepatocellular carcinoma.BMC cancer · 2022Article
- Diagnostic workup of inherited platelet disorders.Blood research · 2022Review
- COVID-19-A Trigger Factor for Severe Immune-Mediated Thrombocytopenia in Active Rheumatoid Arthritis.Life (Basel, Switzerland) · 2022Article
- Platelet variability index: a measure of platelet count fluctuations in patients with immune thrombocytopenia.Blood advances · 2021Article
- Immature Platelet Fraction: Its Clinical Utility in Thrombocytopenia Patients.Journal of laboratory physicians · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe assessment of bone marrow thrombopoietic activity in patients with thrombocytopenia is necessary to achieve an accurate diagnosis and administer effective treatment. We evaluated the discriminatory power of the immature platelet fraction (IPF) in differentiating hyperdestructive/consumptive thrombocytopenia from hypoproductive thrombocytopenia and its potential use as a predictive marker for platelet recovery.
methodsIn this observational study, platelet indices, including IPF, were measured in 105 healthy individuals, 27 patients with hyperdestructive/consumptive thrombocytopenia (all with immune thrombocytopenic purpura [ITP]), and 35 patients with hypoproductive thrombocytopenia (5 with aplastic anemia and 30 with cancer who were undergoing chemotherapy) using a Sysmex XN-3000 hematology analyzer.
resultsThe platelet distribution width, mean platelet volume, platelet large cell ratio, IPF, and absolute immature platelet count (AIPC) were significantly higher in the hyperdestructive/consumptive thrombocytopenia group than in the hypoproductive thrombocytopenia group (P < .001). The IPF showed the highest difference between the two patient groups (200%). Receiver operating characteristics analysis that showed the IPF had the largest area under the curve among all the platelet indices analyzed; its cut-off value was 2.3%. The IPF decreased 3 to 4 days in advance of platelet count elevation in patients with ITP, whereas the delta AIPC increased 3 days in advance. Furthermore, the IPF and delta AIPC increased 5.5 days and 8.5 days, respectively, before platelet counts increased up to 130.0 × 10/L in cancer patients receiving chemotherapy.
conclusionThese data demonstrated that the IPF and delta AIPC are both excellent indicators of the etiology of thrombocytopenia and predictive markers for platelet recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.